CCDRD AG has extensive experience with generic Salmeterol/Fluticasone inhalation product development compared to the available DPI and MDI reference products.
- 25 trials performed with Salmeterol/Fluticasone DPI and MDI inhalers in healthy subjects
- systemic safety and pulmonary deposition studies
- highly experienced investigators and study teams in the phase I units available
- standardized training and clinical procedures
- intrasubject and residual variance data available
- information about product aging available